E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Drug-Resistant Epilepsy with Partial-Onset Seizures |
|
E.1.1.1 | Medical condition in easily understood language |
Epilepsy with Seizures which are partial and are Resistant to therapy |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10065336 |
E.1.2 | Term | Partial epilepsy |
E.1.2 | System Organ Class | 100000004852 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate efficacy of ganaxolone compared to placebo as adjunctive therapy in adults with partial-onset seizures (POS), with or without secondary generalizations. |
|
E.2.2 | Secondary objectives of the trial |
• To evaluate the safety and tolerability of ganaxolone compared to placebo as adjunctive therapy in adults with POS. • To evaluate serum levels of ganaxolone at 1200 mg/d and 1800 mg/d after chronic dosing • To evaluate the safety and tolerability of ganaxolone when administered as adjunctive therapy in adults with POS over a 12-month period. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Male and female subjects 18 years of age and older able to provide written informed consent with a confident diagnosis of epilepsy with POS with or without secondary generalization with a POS frequency rate of ≥3 POS per 28-day who are currently treated on a stable regimen of AEDs. |
|
E.4 | Principal exclusion criteria |
Subjects must not have previous exposure to ganaxolone, generalized epilepsy, have less than 3 POS seizures per 28-day period or ≥21 seizure-free days. Subject should not have innumerable seizures, more than 100 POS total per each 4-week baseline period. No subjects will be admitted who have an active central nervous system (CNS) infection, demyelinating disease, degenerative neurological disease, CNS disease deemed progressive, clinically unstable psychiatric disorder, suicide attempt within the last 5 years, or current significant suicidal ideation. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Significant reduced in frequency of partial onset seizures, with or without secondary generalizations, in patients treated with Ganaxolone compared to placebo |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
At end of 14 weeks of double blind treatment |
|
E.5.2 | Secondary end point(s) |
• To evaluate the safety and tolerability of ganaxolone compared to placebo as adjunctive therapy in adults with POS. • To evaluate serum levels of ganaxolone at 1200 mg/d and 1800 mg/d after chronic dosing • To evaluate the safety and tolerability of ganaxolone when administered as adjunctive therapy in adults with POS over a 12-month period. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
At every patient visit and at end of 68 weeks of open label treatment |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
the study has two phases: 14 weeks double blind followed by 68 open label phase |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 7 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 20 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Bulgaria |
Germany |
Poland |
Russian Federation |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
the last visit of the last subject undergoing the trial |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |